SLU-PP-332 5 mg

How it works

SLU-PP-332 is widely searched as a "peptide," but published scientific sources describe it more precisely as a synthetic small-molecule agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ), not a conventional amino-acid-chain peptide drug.^[1] ERRs are nuclear receptors related to classical estrogen receptors by structure, but they function independently in the transcriptional control of energy metabolism rather than as hormone receptors in the reproductive sense.

It originates from academic pharmacology research into "exercise mimetics" — compounds designed to reproduce specific molecular effects of exercise — and remains an early-stage laboratory research compound. It is not a marketed supplement, an approved drug, or a peptide in the strict biochemical sense, despite how it is often labeled in consumer content.

Benefits & side effects

Essentially all direct evidence for SLU-PP-332 is preclinical: mouse studies have examined endurance capacity and fatty acid oxidation after ERR activation, and mechanistic work has characterized its receptor-binding and gene-expression effects.^[4] No published human clinical trials of SLU-PP-332 have been identified in major trial registries, and there is no peer-reviewed human efficacy or safety data.

This places SLU-PP-332 at the earliest rung of the evidence ladder — chemistry and animal biology — well below the human pharmacokinetic studies, dose-ranging trials, and randomized controlled trials that would be needed before any claims about human endurance, metabolic health, or body composition could be considered established.